Financial Performance - The company reported a basic earnings per share of 0.1700 yuan for Q1 2025, representing a 13.33% increase compared to 0.1500 yuan in Q1 2024 [1] - The net profit for Q1 2025 was 0.96 billion yuan, up 17.07% from 0.82 billion yuan in Q1 2024 [1] - The operating revenue for Q1 2025 reached 6.27 billion yuan, a 23.18% increase from 5.09 billion yuan in Q1 2024 [1] - The return on equity decreased to 2.80% in Q1 2025 from 3.63% in Q1 2024, a decline of 22.87% [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 13,313.51 million shares, accounting for 24.34% of the circulating shares, which is a decrease of 305.19 million shares from the previous period [1] - Notable shareholders include Shen Jie with 5,613.61 million shares (10.26%), and Nanjing University Capital Operation Co., Ltd. with 1,909.00 million shares (3.49%) [2] - New entrants among the top shareholders include China Industrial Bank's ETF with 1,247.92 million shares (2.28%) [2] Dividend Distribution - The company has announced that there will be no distribution or transfer of dividends this time [3]

Core Insights - Seacoast Banking (SBCF) reported revenue of $140.7 million for Q1 2025, reflecting a 12% increase year-over-year, and EPS of $0.38, up from $0.31 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $136.9 million by 2.77%, while the EPS fell short of the consensus estimate of $0.40 by 5% [1] Financial Performance Metrics - Net Interest Margin was reported at 3.5%, surpassing the average estimate of 3.4% from three analysts [4] - Efficiency Ratio stood at 60.3%, better than the average estimate of 63.1% based on three analysts [4] - Total Net Charge-offs to Average Loans was 0.3%, compared to the estimated 0.2% by two analysts [4] - Total nonperforming loans amounted to $71.02 million, significantly lower than the average estimate of $99.10 million [4] - Total nonperforming assets were reported at $78.19 million, compared to the average estimate of $105.73 million [4] - Average Balance of Total Earning Assets was $13.83 billion, slightly above the estimated $13.79 billion [4] - Total noninterest income was $22.18 million, slightly below the average estimate of $22.45 million [4] - Net interest income (FTE) was $118.86 million, exceeding the average estimate of $115.96 million [4] - Net interest income was reported at $118.52 million, compared to the average estimate of $115.64 million [4] Stock Performance - Shares of Seacoast Banking have returned -9.6% over the past month, underperforming the Zacks S&P 500 composite's -5.1% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

近期福安药业（300194）发布2025年一季报，证券之星财报模型分析如下： 经营业绩 近期福安药业发布的2025年一季报显示，公司业绩出现明显下滑。具体来看，截至本报告期末，公司营 业总收入为4.68亿元，同比下降42.22%；归母净利润为6904.9万元，同比下降43.63%；扣非净利润为 6568.48万元，同比下降43.8%。 单季度数据 主营分类 主营构成 主营收入 收入占比 主营利润 利润占比 毛利率 财务分析 业务评价 证券之星价投圈财报分析工具显示，公司去年的ROIC为5.36%，近年资本回报率一般。公司业绩具有周 期性。去年的净利率为11.63%，算上全部成本后，公司产品或服务的附加值一般。 从单季度数据来看，2025年第一季度营业总收入为4.68亿元，同比下降42.22%；归母净利润为6904.9万 元，同比下降43.63%；扣非净利润为6568.48万元，同比下降43.8%。 主要财务指标 本次财报公布的各项数据指标表现不尽如人意。具体如下： 主营收入构成 根据财报，福安药业的主营收入构成如下表所示： 融资分红 公司自上市以来，累计融资总额为34.66亿元，累计分红总额为6.05亿元，分 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002429 证券简称：兆驰股份 公告编号：2025-019 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 □是 √否 一、主要财务数据 3.第一季度报告是否经审计 ■ （二） 非经常性损益项目和金额 √适用 □不适用 单位：元 ■ （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 √否 其他符合非经常性损益定义的损益项目的具体情况 □适用 √不适用 公司不存在其他符合非经常性损益定义的损益项目的具体情况。 将《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》中列举的非经常性损益项目界 定为经常性损益项目的情况说明 □适用 √不适用 公司不存在将《公开发行证券的公司信息披露解释性公告 ...

Core Insights - SouthState (SSB) reported a revenue of $630.64 million for the quarter ended March 2025, marking a 51.8% increase year-over-year and exceeding the Zacks Consensus Estimate by 2.35% [1] - The earnings per share (EPS) for the quarter was $2.15, up from $1.58 in the same quarter last year, resulting in an EPS surprise of 50.35% compared to the consensus estimate of $1.43 [1] Financial Metrics - Net Interest Margin (Non-Tax Equivalent) was reported at 3.8%, slightly above the estimated 3.6% [4] - The Efficiency Ratio stood at 61%, higher than the average estimate of 57% [4] - Total nonperforming assets were $280.44 million, exceeding the estimated $251.43 million [4] - Net charge-offs as a percentage of average loans (annualized) were 0.4%, compared to the estimated 0.1% [4] - Average Balance of Total interest-earning assets was $57.50 billion, below the estimated $58.46 billion [4] - Net Interest Income was reported at $544.55 million, surpassing the average estimate of $516.19 million [4] - Total Noninterest Income was $86.09 million, slightly below the estimated $88.27 million [4] - Net interest income, tax equivalent (Non-GAAP) was $545.33 million, exceeding the average estimate of $528.97 million [4] Stock Performance - SouthState's shares have returned -5.6% over the past month, compared to a -5.1% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Merit Medical reported revenue of $355.35 million for the quarter ended March 2025, reflecting a year-over-year increase of 9.8% and exceeding the Zacks Consensus Estimate of $352.33 million by 0.86% [1] - The company's EPS for the quarter was $0.86, up from $0.77 in the same quarter last year, resulting in an EPS surprise of 14.67% compared to the consensus estimate of $0.75 [1] Financial Performance Metrics - U.S. sales reached $213.56 million, surpassing the average estimate of $208.66 million by analysts, marking a year-over-year increase of 14.8% [4] - International sales were reported at $141.79 million, slightly below the estimated $143.33 million, with a year-over-year growth of 3.2% [4] - Revenue from Cardiovascular-Peripheral Intervention was $137.28 million, below the average estimate of $141.95 million, showing a 2% increase year-over-year [4] - Cardiovascular-Cardiac Intervention revenue was $99.74 million, exceeding the estimated $98.79 million, with a 10% year-over-year increase [4] - Endoscopy revenue was reported at $16.64 million, below the average estimate of $17.89 million, but reflecting a significant year-over-year increase of 64.2% [4] - Cardiovascular-OEM revenue reached $53.75 million, surpassing the average estimate of $43.84 million, with a year-over-year increase of 36.9% [4] - Total Cardiovascular revenue was $338.71 million, slightly above the estimated $334.45 million, representing an 8.1% year-over-year increase [4] - Revenue from Cardiovascular-Custom Procedural Solutions was $47.94 million, below the average estimate of $49.74 million, indicating a year-over-year decline of 1.8% [4] Stock Performance - Over the past month, Merit Medical's shares have returned -9.6%, compared to a -5.1% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.0814 | 0.0662 | 22.96 | 0.0912 | | 每股净资产（元） | 5.71 | 5.3 | 7.74 | 4.82 | | 每股公积金(元) | 1.43 | 1.5 | -4.67 | 1.5 | | 每股未分配利润(元) | 2.88 | 2.56 | 12.5 | 2.11 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 39.7 | 38.01 | 4.45 | 30.75 | | 净利润(亿元) | 0.82 | 0.67 | 22.39 | 0.92 | | 净资产收益率(%) | 1.42 | 1.22 | 16.39 | 1.86 | 数据四舍五入，查看更多财务数据>> 前十大流通股东累计持有： 33527.28万股，累计占流通股比： 33.36%，较上期变化： -689.69万股。 | 名称 ...

一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.0173 | -0.0230 | 24.78 | -0.0267 | | 每股净资产（元） | 0.69 | 0.67 | 2.99 | 0.02 | | 每股公积金(元) | 1.18 | 1.19 | -0.84 | 1.19 | | 每股未分配利润(元) | -1.65 | -1.67 | 1.2 | -2.32 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 1.36 | 1.72 | -20.93 | 1.06 | | 净利润(亿元) | -0.17 | -0.23 | 26.09 | -0.27 | | 净资产收益率(%) | -2.44 | -3.43 | 28.86 | -83.82 | 数据四舍五入，查看更多财务数据>> 三、分红送配方案情况 本次公司不分配不转赠。 二、前10名无限售条件股东持股情况 前十大流通股 ...

一、主要会计数据和财务指标 前十大流通股东累计持有： 7257.24万股，累计占流通股比： 66.7%，较上期变化： 5752.03 万股。 | 名称 | 持有数量(万股) | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 常州祥兴信息技术有限公司 | 5595.13 | 51.43 | 新进 | | 常州祥华管理咨询有限公司 | 376.88 | 3.46 | 新进 | | 宁波祥光创业投资合伙企业(有限合伙) | 354.36 | 3.26 | -40.00 | | 昆山超辉股权投资合伙企业(有限合伙) | 267.20 | 2.46 | 不变 | | 杨剑东 | 188.65 | 1.73 | 不变 | | 杨剑平 | 188.65 | 1.73 | 不变 | | 沈夏青 | 89.50 | 0.82 | 17.50 | | 杨剑芬 | 75.46 | 0.69 | -4.39 | | 吕仕铭 | 69.48 | 0.64 | 新进 | | 民生证券投资有限公司 | 51.93 | 0.48 | -108.70 | | 较上个报告期退出前十大股东有 ...

Financial Data and Key Metrics Changes - Revenue for the first quarter was $82.9 million, down 2% year over year, but within the upper end of guidance [5][27] - Non-GAAP gross margins were 57.7%, up from 51.8% in the previous year, marking a 590 basis points year-over-year expansion [5][27] - Non-GAAP operating expenses were $38.5 million, down $2.2 million from the previous year [5][28] - Non-GAAP EPS was $0.33, compared to $0.09 in Q1 2024, representing significant growth [6][30] - Adjusted EBITDA was $12.5 million, or 15% of sales, compared to $5.6 million in the previous year [29] Business Line Data and Key Metrics Changes - The Americas and European regions saw a revenue decline of 31% each, while the Asia Pacific region experienced a 1% growth [27] - The company launched several new products, including LEAP and BLINK, which are expected to contribute positively to revenue in the upcoming quarters [12][42] Market Data and Key Metrics Changes - The underlying market conditions remained challenging, particularly in the Americas due to tariff-related uncertainties [10][32] - Despite the difficulties, net orders grew by 6% year over year, indicating a positive trend in backlog [9][10] Company Strategy and Development Direction - The company is focused on a three-phase strategy to create shareholder value, with the first phase emphasizing operational excellence and the second phase targeting organic growth [6][7] - The third phase will involve selective higher-risk investments as the company strengthens its cash position [7] - The company aims to refresh its product portfolio and develop global partnerships to drive growth [9][12] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the macro environment, noting that demand is currently outpacing Q1 levels [25][40] - The company is prepared for potential challenges related to tariffs and has plans in place to mitigate impacts [20][21] - Management believes that tariffs could ultimately become a net positive as companies look to diversify supply chains [25] Other Important Information - The company has established a strong cash position, with cash and short-term investments totaling $102.6 million at the end of the quarter [30] - The company is actively managing its partnerships and expects contributions from new agreements in the upcoming quarters [17][18] Q&A Session Summary Question: How is the hardware business shaping up for Q2? - Management noted that while they historically see a larger portion of revenues late in the quarter, they are currently seeing a decent start to Q2, with cautious optimism despite planning for a potential 10% decline in the hardware market [37][39] Question: What is the expected impact of new products on Q2? - Management indicated that new products like LEAP and BLINK are expected to contribute positively in Q2, with strong pre-orders for BLINK already noted [41][42] Question: Can you provide insights on order growth and backlog? - Management clarified that the order growth was not specifically aimed at building backlog, but they did see some late orders that could help solidify their outlook for Q2 [52][55] Question: Are there any delays in product launches or partnerships due to the current environment? - Management confirmed that they do not anticipate delays in product launches or partnerships, viewing the current environment as an opportunity for growth [56][58]